Enzymotec Ltd
ENZY
ENZY was delisted on the 10th of January, 2018.
20 hedge funds and large institutions have $57.8M invested in Enzymotec Ltd in 2015 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
5% more funds holding
Funds holding: 19 → 20 (+1)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
11% less capital invested
Capital invested by funds: $64.9M → $57.8M (-$7.04M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AP
Alydar Partners
Boston,
Massachusetts
|
+$441K |
| 2 |
Goldman Sachs
New York
|
+$401K |
| 3 |
Renaissance Technologies
New York
|
+$383K |
| 4 |
VAM
Visium Asset Management
New York
|
+$248K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$138K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MACM
March Altus Capital Management
Greenwich,
Connecticut
|
-$5.13M |
| 2 |
D.E. Shaw & Co
New York
|
-$268K |
| 3 |
Millennium Management
New York
|
-$176K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$94.8K |
| 5 |
Morgan Stanley
New York
|
-$77.1K |
ENZY Hedge Fund Activity: Q1 2015 in Review
20 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Enzymotec Ltd (ENZY) for Q1 2015, worth a combined $57.8M — down 11% from $64.9M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ENZY positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Alydar Partners, opening a new position worth an estimated $441K. The largest seller was March Altus Capital Management, exiting entirely with an estimated $5.13M sold.
- 20 institutional investors held Enzymotec Ltd (ENZY) as of Q1 2015, up from 19 in Q4 2014.
- Funds reported $57.8M of Enzymotec Ltd stock for Q1 2015, down 11% quarter-over-quarter.
- 4 funds opened new Enzymotec Ltd positions in Q1 2015 and 3 closed out, a net change of +1 holder.
- The largest Enzymotec Ltd buyer in Q1 2015 was Alydar Partners, an estimated $441K added.
- The largest Enzymotec Ltd seller in Q1 2015 was March Altus Capital Management, an estimated $5.13M sold.
Based on aggregated 13F filings for Q1 2015.